Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Unknown 3

Sponsor Class

OTHER 110INDUSTRY 41NETWORK 5OTHER_GOV 4NIH 4UNKNOWN 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3CNS 1

Conditions

Breast Neoplasms 3Neoplasm Metastasis 1Hormone Receptor Positive Advanced Breast Cancer 1Carcinoma, Ductal, Breast 1Brain Neoplasms 1

Interventions

Paclitaxel 5Capecitabine 5pyrotinib 4Epirubicin 4Docetaxel 4exemestane 3Vinorelbine 3Radiotherapy 3Radiation Dose Hypofractionation 3Fulvestrant 3Carboplatin 3apatinib 2Neoadjuvant Therapy 2Letrozole 2Etoposide 2Cyclophosphamide 2Albumin-Bound Paclitaxel 2toripalimab 1titanium silicide 1pirarubicin 1palbociclib 1nimotuzumab 1icaritin 1anlotinib 1Therapeutics 1Standard of Care 1Radiation 1Pemetrexed 1Nutrition Assessment 1Methods 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
UNKNOWN × Breast Neoplasms × Vinorelbine × Clear all
NCT02768415 2019-06-19

Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer

ChineseAMS

Phase 2 Unknown
40 enrolled
Breast

Breast Neoplasms

NCT03933982 2019-05-29

Pyrotinib

ChineseAMS

Phase 2 Unknown
30 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT01126138 2011-05-04

Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)

ChineseAMS

Phase 3 Unknown
200 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Carcinoma, Ductal, Breast

Data powered by HemOnc (CC BY 4.0) Colophon âš¡